

TEQCool's Strategic Pathway to Market: Saving Lives, Seizing Opportunity, and Scaling Impact

Brain injuries remain one of the most devastating and under-treated global health challenges. TEQCool AB is now taking bold, regulation-aligned steps to bring its groundbreaking non-invasive brain cooling system to clinics—and to the patients who urgently need it.

"Our mission is simple: prevent secondary brain damage before it occurs. Our method is disruptive: rapid, focal brain cooling without the need for sedation or systemic hypothermia. The future of neuroprotection starts here," says Anders Sjögren, CEO of TEQCool.

Clinical Trials Ahead – A Critical Step Toward the Market

Following strong preclinical results, TEQCool is preparing to launch its first clinical trials in the end of 2026, in collaboration with leading neuroclinics in Sweden and across Europe. The initial focus will be on patients suffering from traumatic brain injury and stroke, where the need for rapid neuroprotection is greatest.

The goal is to generate robust clinical data to support CE marking and, in the longer term, regulatory approval in other major markets including the U.S.

Toward the Stock Market – Planned Listing After Summer 2025

As part of its growth strategy, TEQCool plans to go public on a Swedish growth market after the summer of 2025. The listing is intended to secure capital to accelerate regulatory efforts, scale up manufacturing, and prepare for international commercialization.

"We're entering a pivotal phase. With growing interest from both the healthcare sector and investors, now is the time to take the next step. Going public gives us the resources to realize our vision of making rapid, safe brain cooling a new standard in emergency care," says Anders Sjögren.

Strategic Partnerships Aligned with Clinical Studies

In parallel with the clinical trials, TEQCool will also initiate collaborations with potential industrial and commercial partners. These partnerships aim to validate the technology in clinical settings and prepare for future distribution and market access.

"The clinical studies are not only medical proof points—they're also a launchpad for strategic alliances. We see strong interest from medtech companies and healthcare providers who want to be at the forefront of next-generation neuroprotection," Anders Sjögren concludes.

For further information regarding TEQCool, please contact:

Anders Sjögren, CEO TEQCool AB, E-mail: ir@teqcool.com



PRESS RELEASE
19 June 2025 12:30:00 CEST

About Us

TEQCool AB is a medical technology company in Lund, Sweden. TEQCool is developing a unique, patented solution for selective cooling of the brain in patients at risk of oxygen deprivation. The company is initially targeting patients with severe brain damage who suffer from neurological fever, but the need exists in many areas, such as heart attack, stroke, blood poisoning, COVID and other serious viral diseases, neonatal, suicide attempts, etc. The intended therapy is based on many years of research and development at Lund University, as well as preclinical and clinical studies.